This unique focus on CAPS disease of the clinical trials with NLRP3 inhibitors is one of the reasons that MCC950, acknowledged as the most potent NLRP3 inflammasome inhibitor according to the preclinical results, has not been continued into clinics, as binding of MCC950 to NLRP3 has been shown to be impeded by CAPS-associated mutation [117]. This evidence concerns the gene NLRP3 and cryopyrin-associated periodic syndrome.